News
June 24, 2024
Sustained Therapeutics Announces First Patient for Cancer Trial
The first patient has entered the Phase II/III trial of ST-02, Sustained Therapeutic’s innovative cancer medication targeting Upper Tract Urethral Carcinoma (UTUC).
A rare form of cancer, UTUC affects over 7,000 individuals annually across North America. UTUC is a cancer of the inside lining of the kidney (the “collecting system” – where urine starts to drain after it is made by the kidney) and the ureter (the tube that carries urine from the kidney to the bladder).
November 16, 2023
Sustained Therapeutics announces clinical trial of second product
Sustained Therapeutics announced today regulatory clearance for a pivotal Phase II/III human trial of its second product, a novel medication for the treatment of a rare form of cancer. Upper Tract Urethral Carcinoma (“UTUC”) is an orphan disease, a malignancy of the cells lining the renal pelvis. It affects about 6,000 patients each year in North America.
Recruitment ongoing for new therapy to address painful male problem
A new clinical trial is currently recruiting men struggling with a painful, but not uncommon, condition: chronic scrotal pain. The Phase II study is testing an important new therapeutic approach to treat this condition at our centre in Vancouver and in other locations across Canada including Calgary, Winnipeg, Ottawa, Toronto and Montreal and plans to enroll 63 people over the next six months.
July 5, 2023
A successful phase 1 study of an injectable lidocaine paste for spermatic cord block in men with chronic scrotal content pain
Patients with chronic scrotal content pain (CSCP) lack effective, noninvasive
treatment options. We aimed to determine the local and systemic safety, tolerability,
pharmacokinetics (PK), and efficacy of a long-lasting local anesthetic in patients with CSCP.
March 30, 2023
Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform
A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal Pain (CSP), a debilitating condition estimated to affect 1% of the male population. Sustained Therapeutics’ first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single injection.
January 5, 2023
Sustained Therapeutics Advancing Clinical Trials for Novel Drug Delivery Platform
A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics is evaluating a sustained release platform technology that could revolutionize how we treat pain and significantly improve the lives of individuals living with chronic pain.
